Methotrexate and KRYSTEXXA (pegloticase) Study for Chronic Gout

Dr. John Albert, a rheumatologist at the Rheumatic Disease Center in southeastern Wisconsin, discusses a new in-practice patient series presented at the American College of Rheumatology (ACR) Annual Meeting 2019. The series looked at how methotrexate may attenuate the immune response to KRYSTEXXA to allow more patients on KRYSTEXXA to continue their treatment, helping to inform rheumatologists on effective treatment practices to control the serious and chronic disease of gout.

John A. Albert, M.D., M.B.A., is dedicated to providing innovative patient care as a rheumatologist at the Rheumatic Disease Center in southeastern Wisconsin. He is a passionate gout specialist, sharing knowledge and experience to help change perceptions of this often-overlooked rheumatic disease and ultimately improve care for his patients and others living with the disease. Dr. Albert brings over 25 years of experience to the practice. He received his M.D. at Stanley Medical College and his M.B.A at the University of Wisconsin. Dr. Albert’s postdoc fellowship was in Rheumatology at the University of Wisconsin.